ICIs Increase pCR Rates in Early ER+/HER2 Breast Cancer.

Published Date: 24 Oct 2023

Two randomized trials showed that patients with early high-risk estrogen receptor?positive, HER2-negative breast cancer benefited from the addition of immune checkpoint inhibitors to neoadjuvant chemotherapy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot